Clinical Trial

PH 2 Pemigatinib in SDH-deficient GIST

Study acronym: PEMIGIST
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine how effective the drug pemigatinib is as a treatment option for advanced succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors(GIST). This study will also assess the side effects associated with pemigatinib and evaluate its tolerability. The name of the study drug involved in this study is: • Pemigatinib (INCB054828)
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-22
Trial Details
NCT Number NCT07434843
Lead Sponsor Dana-Farber Cancer Institute
Collaborators: Gateway for Cancer Research, Incyte Corporation
Conditions SDH Gene Mutation, Gastrointestinal Stromal Tumor
Enrollment 24 participants
Start Date 2026-05-19
Primary Completion 2028-10-01 (estimated)
Study Completion 2029-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-22